Thermo Fisher Scientific Inc. (NYSE:TMO) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on Thermo Fisher Scientific, with 17 buy, 2 strong-buy, 5 hold and 2 sell ratings. The average 12-month price target is $624.64.
• Thermo Fisher reported quarterly EPS of $6.03, exceeding the $5.71 consensus, while revenue reached $11.99 billion and rose 10.5% year over year. The company forecasts fiscal 2026 EPS of $24.93–$25.33.
• The company declared a quarterly dividend of $0.47 per share, equivalent to a $1.88 annualized payout and a 0.3% yield. Insiders have sold 73,768 shares worth $44.1 million over the past 90 days, while institutional investors own 89.23% of the stock.

Shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) have been given an average rating of "Moderate Buy" by the twenty-six analysts that are currently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, five have issued a hold recommendation, seventeen have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $624.6364.

Several analysts have commented on the stock. UBS Group raised shares of Thermo Fisher Scientific from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $540.00 to $730.00 in a research report on Tuesday, September 8th. Stifel Nicolaus set a $650.00 price target on Thermo Fisher Scientific in a research report on Wednesday, August 5th. Royal Bank Of Canada increased their price objective on Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a "sector perform" rating in a report on Friday, July 24th. Wolfe Research assumed coverage on Thermo Fisher Scientific in a report on Tuesday, June 2nd. They issued an "outperform" rating and a $535.00 target price for the company. Finally, Wells Fargo & Company downgraded Thermo Fisher Scientific from an "overweight" rating to an "underweight" rating in a report on Wednesday, September 9th.

Thermo Fisher Scientific Stock Down 1.1%

Thermo Fisher Scientific stock opened at $650.82 on Friday. Thermo Fisher Scientific has a twelve month low of $435.27 and a twelve month high of $663.57. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The firm has a market cap of $240.64 billion, a PE ratio of 35.01, a P/E/G ratio of 2.75 and a beta of 0.85. The firm's 50 day moving average price is $592.80 and its two-hundred day moving average price is $522.93.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating analysts' consensus estimates of $5.71 by $0.32. The firm had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business's quarterly revenue was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, research analysts predict that Thermo Fisher Scientific will post 25.13 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.11%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Michael Shafer sold 25,500 shares of the firm's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the sale, the executive vice president owned 20,994 shares of the company's stock, valued at $12,596,400. This trade represents a 54.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc Casper sold 275 shares of the company's stock in a transaction on Monday, August 24th. The shares were sold at an average price of $627.05, for a total transaction of $172,438.75. Following the transaction, the chief executive officer owned 123,925 shares of the company's stock, valued at approximately $77,707,171.25. The trade was a 0.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 73,768 shares of company stock worth $44,122,820 in the last 90 days. 0.33% of the stock is owned by company insiders.

Institutional Investors Weigh In On Thermo Fisher Scientific

Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. acquired a new position in Thermo Fisher Scientific in the second quarter worth about $15,501,867,000. Corient Private Wealth LP acquired a new stake in Thermo Fisher Scientific during the second quarter valued at approximately $382,547,000. Norges Bank acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $3,072,744,000. Bank of New York Mellon Corp bought a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $1,974,561,000. Finally, Bank of America Corp DE bought a new stake in Thermo Fisher Scientific in the second quarter valued at $1,952,930,000. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of scientific equipment, laboratory services and analytical technologies. The company serves pharmaceutical and biotechnology companies, clinical laboratories, academic and government institutions, industrial businesses and other research organizations.

Its products and services include laboratory instruments, analytical systems, reagents, consumables, software and related services. Thermo Fisher also provides laboratory supplies and equipment, bioproduction solutions, genetic analysis technologies, clinical diagnostics, specialty diagnostic products and contract research and manufacturing services through its laboratory services businesses.

The company was formed in 2006 through the merger of Thermo Electron Corporation and Fisher Scientific International.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.